Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Assessment of treatment response in cardiac sarcoidosis based on myocardial F-FDG uptake.
Front Immunol
December 2023
Department of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland.
Article Synopsis
- The study aimed to examine the effectiveness and safety of non-biological and biological disease-modifying anti-rheumatic drugs (nb/bDMARDs) for treating cardiac sarcoidosis (CS), focusing on myocardial inflammation measured by F-FDG PET/CT.!
- A retrospective analysis of 50 CS patients showed that while most were treated with prednisone and nb/bDMARDs, only adalimumab significantly reduced cardiac metabolic activity on follow-up scans compared to other treatments.!
- TNF inhibitors (TNFi) not only provided better control over myocardial inflammation but were also safe and improved heart function in patients with severely reduced left ventricular ejection fraction (LVEF).!*
Rectal delivery of Zr-labeled infliximab-loaded nanoparticles enables PET imaging-guided localized therapy of inflammatory bowel disease.
J Mater Chem B
December 2023
NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, P. R. China.
Inflammatory bowel diseases (IBDs) like Crohn's disease and ulcerative colitis involve chronic gastrointestinal inflammation. The pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-α) drives IBD pathogenesis. Anti-TNF-α therapies using monoclonal antibodies (mAbs) like infliximab (INF) help treat IBD but have limitations.
View Article and Find Full Text PDFImmuno-PET Imaging of TNF-α in Colitis Using Zr-DFO-infliximab.
Mol Pharm
October 2022
School of Pharmacy, Nanjing Medical University, Nanjing 211166, PR China.
Tumor necrosis factor-alpha (TNF-α) neutralization has become increasingly important in the treatment of inflammatory bowel diseases (IBD). A series of monoclonal antibodies were approved in the clinic for anti-TNF-α therapy. However, a comprehensive assessment of TNF-α levels throughout the colon, which facilitates the diagnosis of IBD and predicts anti-TNF-α efficacy, remains challenging.
View Article and Find Full Text PDFEffects of Anti-Tumor Necrosis Factor Therapy on Osteoblastic Activity at Sites of Inflammatory and Structural Lesions in Radiographic Axial Spondyloarthritis: A Prospective Proof-of-Concept Study Using Positron Emission Tomography/Magnetic Resonance Imaging of the Sacroiliac Joints and Spine.
Arthritis Rheumatol
September 2022
Rheumazentrum Ruhrgebiet, Herne, and Ruhr-University Bochum, Bochum, Germany.
Objective: Proof-of-concept trial to determine the effects of tumor necrosis factor inhibitor (TNFi) therapy on osteoblastic activity at sites of inflammatory and structural lesions in patients with radiographic axial spondyloarthritis (SpA), using fluorine 18-labeled NaF ( F-NaF) positron emission tomography/magnetic resonance imaging (PET/MRI).
Methods: Sixteen patients with clinically active radiographic axial SpA were prospectively enrolled to receive TNFi treatment and undergo F-NaF PET/MRI of the sacroiliac (SI) joints and spine at baseline and at a follow-up visit 3-6 months after treatment initiation. Three readers (1 for PET/MRI and 2 for conventional MRI) evaluated all images, blinded to time point.
99mTc-antitumor necrosis factor-alpha scintigraphy for the detection of inflammatory activity in rheumatoid arthritis.
Nucl Med Commun
April 2021
Department of Radiology, School of Medicine, Federal University of Rio de Janeiro.
Objective: Tumor necrosis factor-alpha (TNF-α) is an important inflammatory cytokine. 99mTc-anti-TNF-α antibody scintigraphy has proven to be a viable alternative to MRI in specific cases. The objective of this study was to evaluate the performance of scintigraphy with 99mTc-anti-TNF-α in the identification of inflammatory foci in individuals diagnosed with rheumatoid arthritis using MRI as the gold standard.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!